In The News

Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?

Worried About Biogen’s Aducanumab? Don’t Be

Aducanumab Reinvigorates the Fight Against Alzheimer Disease

Alzheimer’s Disease Treatment: Canadian-Led Innovation Post-Aducanumab

Buffett's a believer: Berkshire bets $192M on Biogen ahead of key Alzheimer's filing

Getting on Target for Alzheimer’s

Biogen Reports Drug Effective in Slowing Alzheimer’s Disease: ‘A Milestone Achievement’

Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep

Financial Times – Alzheimer’s drug revival gives hope to millions — and investors

STAT – Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs